CAMBRIDGE, England, AHMEDABAD, India and NORTH BRUNSWICK, New Jersey, June 23, 2011 /PRNewswire/ --
Oxygen Healthcare Ltd. (O2h), a Piramal Group Company and Chromocell Corporation, an emerging life sciences company active in both flavors and therapeutics discovery, today signed an agreement under which O2h will provide supplemental chemistry support to further accelerate the drug discovery initiatives at Chromocell.
"I have known O2h for a number of years and am impressed by its delivery focus," said David Palling, Senior Vice President, Therapeutics, Chromocell. "With the in-house chemistry resources and the faster-than-expected progress made in our therapeutic programs, complementary support from O2h will help us maximize resources and reach our end-points quicker. I look forward to this opportunity of working with them to advance our drug discovery pipeline."
O2h will provide Chromocell during 2011 with focused libraries of compounds at mg-g scale for various projects.
Sunil Shah, CEO, O2h said "O2h has optimized its operations for discovery speed and delivery to help accelerate drug discovery efforts of companies in the United States, Europe and Japan. It is our privilege to work with the experienced team led by Dr. Palling at Chromocell,"
About Chromocell Corporation
Chromocell, founded in 2002 and headquartered in North
Brunswick, N.J., is an emerging life sciences company which
improves consumer products and patient lives through breakthrough
science and technologies. It is focused on the discovery and
development of both flavors and therapeutics through its pioneering
Chromovert ® technology, a process that enables the company to use
naturally occurring systems that mimic human biology as part of its
discovery platform. Chromocell works with worldwide consumer
goods companies to develop fla
Copyright©2010 PR Newswire.
All rights reserved